Drug Kinetics – Multimedia
Video
Safety Considerations for the Development of Antibody Drug Conjugates
Both the antibody and small molecule of an ADC can contribute to drug interactions, so they should be considered from a safety perspective. However, regulatory guidance is not well established. Here’s what you need to know.
Video
Rapid Quantitation of AAV Capsids in Bioprocess Development for Gene Therapy Using Octet®️ BLI
Accelerate bioprocessing in gene therapy. Adeno-associated virus (AAV) capsid quantitation in as little as 15 minutes using Octet® BLI systems. Compare the Octet® AAVX biosensor workflow to that of ELISA at various stages in bioprocess development.
Video
Accelerate Throughput and Discovery for Your Mass Spec Imaging Projects
With unparalleled speed, sensitivity and spatial resolution, Shimadzu’s iMScope QT imaging mass microscope clears the way to next-generation mass spectrometry imaging in areas such as biomarker tracking, pharmacokinetics, and ADME studies.
Poster
Kinetic Analysis: Spotting the Weakest Binders
Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.
How To Guide
Revolutionary Binding Kinetics Analysis
Conventional bioassays often require labeled detection reagents to provide a measurable readout. However, modifications to molecular structure and/or function can skew results, and non-specific binding of the labels themselves can lead to an unwanted background signal.
Video
Design Intricacies and Decision Making Strategy for Drug Drug Interaction Studies
Conducting in vitro ADME drug-drug interaction (DDI) studies early on in the drug development process is more than simply a box checking exercise to satisfy regulatory requirements. The information provided by these studies provides a deeper understanding of the molecule to the drug developer helping to inform go or no-go decisions early on.
Video
Highlights of the In Vitro Sections of the Draft ICH Drug Interaction Studies Guideline and Comparison with Current Guidance
Hear expert Dr. Brian Ogilvie discuss the differences between current in vitro drug-drug interaction guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan drug development strategies to meet the ICH M12 guideline.
Video
Filing an IND and Beyond: Development of CTD Section 2.6.4, Pharmacokinetics Written Summary
This presentation was one of the keynote presentations from XenoTech's XenoTalks™ Seminar Series on the importance of ADME and Drug-Drug Interactions in drug development.
Video
Model-Based Approaches to DDI Risk Prediction-Transitioning from In Vitro Data to In Silico Modeling
This informative ADME 101 discusses In Vitro to In Vivo Extrapolation (IVIVE) and how a model-based approach following routine perpetrator potential studies (i.e. CYP inhibition, CYP induction, and transporter inhibition) assessing clinical potential may eliminate the need of conducting clinical studies.
Video
Advances in High Throughput Analysis of In-Vitro Drug Screening Using the Novel Echo® MS System
Speaking at Advances in Drug Discovery & Development online symposium 2021, Rolf Kern from SCIEX, presented his talk on the new Echo MS system.
Advertisement